- Home
- APM vs OGEN Comparison
APM vs OGEN Comparison
Compare APM & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- OGEN
- Stock Information
- Founded
- APM 2010
- OGEN 1996
- Country
- APM United Kingdom
- OGEN United States
- Employees
- APM N/A
- OGEN N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- APM Health Care
- OGEN Health Care
- Exchange
- APM Nasdaq
- OGEN Nasdaq
- Market Cap
- APM 4.0M
- OGEN 4.5M
- IPO Year
- APM 2018
- OGEN N/A
- Fundamental
- Price
- APM $0.74
- OGEN $0.34
- Analyst Decision
- APM
- OGEN
- Analyst Count
- APM 0
- OGEN 0
- Target Price
- APM N/A
- OGEN N/A
- AVG Volume (30 Days)
- APM 69.7K
- OGEN 269.0K
- Earning Date
- APM 12-27-2024
- OGEN 11-13-2024
- Dividend Yield
- APM N/A
- OGEN N/A
- EPS Growth
- APM N/A
- OGEN N/A
- EPS
- APM N/A
- OGEN N/A
- Revenue
- APM $431,378.00
- OGEN N/A
- Revenue This Year
- APM $157,729.10
- OGEN N/A
- Revenue Next Year
- APM N/A
- OGEN N/A
- P/E Ratio
- APM N/A
- OGEN N/A
- Revenue Growth
- APM N/A
- OGEN N/A
- 52 Week Low
- APM $0.46
- OGEN $0.25
- 52 Week High
- APM $17.49
- OGEN $7.74
- Technical
- Relative Strength Index (RSI)
- APM 41.12
- OGEN 49.33
- Support Level
- APM $0.73
- OGEN $0.32
- Resistance Level
- APM $0.78
- OGEN $0.38
- Average True Range (ATR)
- APM 0.09
- OGEN 0.03
- MACD
- APM 0.04
- OGEN 0.00
- Stochastic Oscillator
- APM 64.47
- OGEN 38.89
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.